Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Se
- This topic has 3 replies, 2 voices, and was last updated 5 years, 7 months ago by
.
-
Posts
-
My husband had great partial response to Pemigatinib: I believe he had the best result of all on the trial. Unfortunately, the response stopped and over 2 scans he has had growth. Incyte removed him from the trial after cycle 26. This drug was terrific while it lasted. Hope others have the same kind of results.
Hi Kgroft,
Glad to be of help as always. Thanks for letting us know about your husband and I am very happy to hear how he is getting on with this. I will keep my fingers crossed for him for further great responses to the treatment and please if you can keep letting us know how things go with this. We are here for you.
My best wishes to you both,
Gavin
I’m so happy to say my husband is in cohort A and is one of the 19 individuals with Partial Response: he’s had 69% total shrinkage, even though he missed two cycles of the med due to surgery and a hospitalization. This drug has been an incredible gift for him. Our nurse explained that those with FGFR2 KIAA 12-17 seem to have the best response.
Thank you VERY much for posting the link to the article. 🙂
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
- The forum ‘Clinical Trials’ is closed to new topics and replies.